BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO), has approved the nonproprietary name “adipiplon” for Neurogen’s wholly-owned drug candidate for treatment of insomnia, NG2-73.
